[HTML][HTML] EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head
J Clark, J Cools, DG Gilliland - PLoS medicine, 2005 - journals.plos.org
J Clark, J Cools, DG Gilliland
PLoS medicine, 2005•journals.plos.orgEGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly
Head | PLOS Medicine Skip to main content Advertisement PLOS Medicine Browse Current
Issue Journal Archive Special Issues Collections Find and Read Articles Publish
Submissions Getting Started Submission Guidelines Figures Tables Supporting Information
LaTeX Other Article Types Preprints Revising Your Manuscript Submit Now Policies Best
Practices in Research Reporting Human Subjects Research Animal Research Competing …
Head | PLOS Medicine Skip to main content Advertisement PLOS Medicine Browse Current
Issue Journal Archive Special Issues Collections Find and Read Articles Publish
Submissions Getting Started Submission Guidelines Figures Tables Supporting Information
LaTeX Other Article Types Preprints Revising Your Manuscript Submit Now Policies Best
Practices in Research Reporting Human Subjects Research Animal Research Competing …
Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance?
PLOS